Fermenta Biotech Ltd
Fermenta Biotech Q2 FY26: Capex ₹12 Cr
Q2 FY26 investor presentation: what the company reported on revenue, margins and projects.
Based on Fermenta Biotech Ltd's Q2 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.
The short version
Q2FY26 Revenue: INR 135.7 crore, up 39% YoY - H1FY26 Revenue: INR 280.7 crore, up 57% YoY - Human nutrition segment volumes grew 74% over H1FY25 - Animal nutrition segment volumes grew 6% over H Q2FY26 Financials: - EBITDA: ₹32.1 crore (up 48% YoY) - Profit after tax (PAT): ₹18.0 crore (up 62% YoY) - Revenue: ₹135.7 crore (up 39% YoY) - H1FY26 Financial Highlights: - EBITDA: ₹69.1 crore (up 173% YoY) - PAT: ₹39.6 crore (up 664% YoY) - Revenue: ₹280.7 crore (up 57% YoY) - EBITDA Margin: sustained at 25.9% for H1FY26 - Net Profit Margin: 14.9% in H1FY26 (from Performance Ratios on page 10) - Margin Outlook: - No explicit future margin guidance or outlook is provided in the presentation.
From Fermenta Biotech Ltd's Q2 FY26 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Q2FY26 Revenue: INR 135.7 crore, up 39% YoY
- H1FY26 Revenue: INR 280.7 crore, up 57% YoY
- Human nutrition segment volumes grew 74% over H1FY25
- Animal nutrition segment volumes grew 6% over H1FY25; average realization rose 35%
2 more points management made on revenue & sales performance
Profitability & Margins
See what Fermenta Biotech Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- H1FY26 investing cash flow shows ₹12 crore spent on Capex for growth initiatives (Page 8).
- No specific details of capacity expansion or new plant/project mentioned; only reference to "strategic capital investment" deployed for growth initiatives (Page 8).
- In September 2025, the board approved the transfer of the Environment Division as a going concern to a wholly owned subsidiary for INR 19 crore; effective 1 October 2025 (Page 5).
- No explicit timelines or descriptions for new plants or capacity expansions detailed in the presentation beyond the above.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Fermenta Biotech Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points management made on order book & pipeline
Fermenta Biotech Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹122 Cr, net profit ₹19 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Fermenta Biotech Ltd's management said in earlier quarters
- Q4 FY24 earnings call analysis →
- Q1 FY25 earnings call analysis →
- Q4 FY25 earnings call analysis →
- Q2 FY25 earnings call analysis →
- Q4 FY22 earnings call →
- Q3 FY22 earnings call →
- Q2 FY22 earnings call →
- Q1 FY22 earnings call →
- Q1 FY22 earnings call →
- Q3 FY21 earnings call →
- Q2 FY21 earnings call →
- Q2 FY21 earnings call →
Others in Pharmaceuticals & Biotechnology this season
- Morepen Laboratories Ltd (Q2 FY26)
248 Crores . Key concall takeaways from Morepen Laboratories Ltd's Q2 FY26 earnings call — and how it ranks against sector peers.
- Jubilant Pharmova Ltd (Q2 FY26)
Q2’FY26 revenue grew by 12% YoY to Rs. Key concall takeaways from Jubilant Pharmova Ltd's Q2 FY26 earnings call — and how it ranks against sector peers.
- Anuh Pharma Ltd (Q2 FY26)
185.88 Cr, a -0.32% change quarter-on-quarter; 6 months ended 30/09/2025: Rs. Key concall takeaways from Anuh Pharma Ltd's Q2 FY26 earnings call — and how it…
- Themis Medicare Ltd (Q2 FY26)
Q2 FY26 Net Revenue: ₹77.99 Cr, down 33.3% YoY from ₹117.01 Cr in Q2 FY25 (Page 8) . Key concall takeaways from Themis Medicare Ltd's Q2 FY26 earnings call…
Frequently Asked Questions
What were Fermenta Biotech Ltd Q2 FY26 results?
Q2FY26 Revenue: INR 135.7 crore, up 39% YoY - H1FY26 Revenue: INR 280.7 crore, up 57% YoY - Human nutrition segment volumes grew 74% over H1FY25 - Animal nutrition segment volumes grew 6% over H Q2FY26 Financials: - EBITDA: ₹32.1 crore (up 48% YoY) - Profit after tax (PAT): ₹18.0 crore (up 62% YoY) - Revenue: ₹135.7 crore (up 39% YoY) - H1FY26 Financial Highlights: - EBITDA: ₹69.1 crore (up 173% YoY) - PAT: ₹39.6 crore (up 664% YoY) - Revenue: ₹280.7 crore (up 57% YoY) - EBITDA Margin: sustained at 25.9% for H1FY26 - Net Profit Margin: 14.9% in H1FY26 (from Performance Ratios on page 10) - Margin Outlook: - No explicit future margin guidance or outlook is provided in the presentation.
What is Fermenta Biotech Ltd share price analysis?
Fermenta Biotech Ltd currently shows a neutral. The stock trades at a P/E of 25.5 with a market cap of ₹1,395 Cr. Investors should review the full earnings analysis for detailed insights.
Is Fermenta Biotech Ltd planning capital expenditure?
H1FY26 investing cash flow shows ₹12 crore spent on Capex for growth initiatives (Page 8).
Keep Fermenta Biotech Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.